EKF Diagnostics Holdings (LSE:EKF), the maker of point-of-care testing equipment and enzymes for the life sciences industry, has told investors it remains on track for its full-year expectations after a first half of stable Revenue and higher margins. Interim results for the six months to 30 June 2026, published in mid-September 2026, showed revenue of £25.0m, adjusted EBITDA up 2.4% to £5.9m and a cash balance of £16.0m.
Company Overview
EKF operates in two broad areas. Its Point-of-Care Business makes analysers and tests used in clinics and hospitals, including beta-hydroxybutyrate (β-HB) measurement products. Its Life Sciences business produces enzymes and other materials through fermentation, including at its Facility in south Wales, and the group also offers contract manufacturing.
This combination gives LSE:EKF two distinct revenue streams: finished diagnostic products sold through healthcare channels, and ingredients and materials supplied to other manufacturers. The enzymes made through fermentation are used as components in diagnostic tests and other life sciences applications.
The β-HB products measure ketones in the blood, a parameter used in the management of diabetes, and the company has built that Franchise alongside its wider range of point-of-care analysers. Fermentation capability is a differentiating feature of the group, as it allows EKF to produce certain enzymes in its own facility rather than relying entirely on outside suppliers.
Latest Developments
A first-half trading update in late July 2026 gave the first indication of the period's performance, putting revenue at about £25.0m compared with £25.2m a year earlier. It reported Life Sciences revenue up about 20%, β-HB revenues up 4% and good performance in contract manufacturing. The update also referred to a share buyback, with £0.9m allocated.
The interim results confirmed that picture, describing Life Sciences as performing well and Point-of-Care revenues as recovering. The company said it had a committed order book for the second half and expected full-year growth in line with consensus. The July update cited consensus forecasts for 2026 of £54.7m revenue and £13.6m adjusted EBITDA.
The figures build on the previous year. In July 2025, the company reported net cash of £14.4m at 30 June 2025 and said Demand for enzymes was driving growth in Life Sciences. Chief executive Mike Salter said then that the business was focused on disciplined cost control and organic growth, and the group was investing in fermentation capacity at its south Wales site to meet that demand.
The comparison with 2025 shows a business that has been steadily rebuilding its cash position while continuing to invest. Net cash of £14.4m a year earlier has been followed by a cash balance of £16.0m, even after funds were allocated to the share buyback programme.
Financial Picture
Gross profit was £13.3m in the half, giving a gross Margin of about 53%, up from roughly 50% a year earlier. Profit before tax was reported at £3.4m. Cash stood at £16.0m at 30 June 2026, and the July update said the group had no bank borrowings.
The interim announcement did not refer to an interim dividend, so shareholders may wish to consult the full statement for the latest position. The company has been returning cash through its share buyback programme, which gives it a way to distribute surplus cash while retaining funds for Investment in capacity.
Adjusted EBITDA, which excludes certain items to show underlying operating performance, rose 2.4% to £5.9m despite revenue being marginally lower than a year earlier. That pattern is consistent with the improvement in gross margin, and with the growth reported by the Life Sciences division, where enzyme demand has been a driver.
Sector and index Context
EKF is part of the healthcare segment of the FTSE AIM All Share Index. Diagnostics companies have had to adjust to the end of pandemic-era testing demand, with attention shifting to routine testing, chronic disease management and Supply to pharmaceutical and biotechnology customers. Demand for enzymes produced through fermentation has been one of the more active areas for the group.
Within that landscape, EKF has the advantage of serving both the clinical diagnostics market and the wider life sciences supply chain, which can reduce reliance on any single customer group or testing trend.
Factors to Monitor
Point-of-Care sales depend on purchasing by healthcare systems and distributors in many countries, so the timing of orders can vary from period to period. The second-half weighting implied by the full-year outlook means delivery of the committed order book is an important milestone. Investment in Manufacturing capacity is designed to support Life Sciences growth, and currency movements can influence the translation of overseas earnings.
What to Watch Next
Market participants will look for a trading update around the year end showing whether second-half orders have converted into revenue, progress on the share buyback and further development in Life Sciences. Full-year results for 2026 from LSE:EKF are expected in 2027.
The share buyback is another item to follow, as the company has set aside £0.9m for it and has described its Balance Sheet as free of bank borrowings. Updates on fermentation capacity at the south Wales site will also indicate how EKF is positioning itself to meet demand for enzymes in the years ahead.






Please wait processing your request...